Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 30

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 30
---
 such capital raising would result
in an equity issuance above regulatory thresholds and, consequently, we could be unable to obtain financing sufficient to sustain our
business if we are unsuccessful in soliciting requisite shareholder approvals.

Our ability to access equity
capital is limited by ASX Listing Rule 7.1, which provides that a company may not, subject to certain exceptions for certain types of
offering ( e. g., rights offers) or approval by shareholders, issue or agree to issue during any consecutive 12-month period
any equity securities, or other securities with rights to conversion to equity, if the number of those securities in aggregate would exceed
15% of the number of ordinary securities on issue at the commencement of that 12-month period.

Our equity issuances will
be limited by ASX Listing Rule 7.1 as long as we continue to be listed on the ASX and this constraint may prevent us from raising the
full amount of equity capital needed for operations without prior shareholder approval or structuring the capital raising within one of
the exceptions to this limitation such as a rights offer.

We are subject to risks associated with
currency fluctuations, and changes in foreign currency exchange rates could impact our results of operations.

Our ordinary shares are
quoted in Australian dollars on the ASX and the ADSs are quoted in U. S. dollars. Any significant change in the value of the
Australian dollar may have a negative effect on the value of the ADSs in U. S. dollars. In addition, if the Australian dollar weakens
against the U. S. dollar, then, if we decide to convert our Australian dollars into U. S. dollars for any business purpose,
appreciation of the U. S. dollar against the Australian dollar would have a negative effect on the U. S. dollar amount available to
us. To the extent that we need to convert U. S. dollars we receive into Australian dollars for our operations, appreciation of the
Australian dollar against the U. S. dollar would have a negative effect on the Australian dollar amount we would receive from the
conversion. Consequently, appreciation or depreciation in the value of the Australian dollar relative to the U. S. dollar would
affect our financial results reported in U. S. dollar terms without giving effect to any underlying change in our business or results
of operations. As a result of such foreign currency fluctuations, it could be more difficult to detect underlying trends in our
business and results of operations.

Our ADS holders are not shareholders and